Leafllet Froben Tablets
Size: 161mm x 136mm
Date: 19-08-2015, 20-08-2015
Ammara Commercial Printers (Pvt.) Ltd.

Froben (Flurbiprofen) Tablets

PRODUCT DESCRIPTION
Froben is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic activity. Its molecular weight is 244.269 and its chemical formula is C15H13FO2. Its chemical name is 2-(2-fluorobiphenyl-4-yl) propionic acid.

INDICATIONS
Flurbiprofen is indicated for the treatment of inflammatory conditions due to osteoarthritis and rheumatoid arthritis. It is contraindicated in patients with a history of severe heart failure, renal failure or hepatic failure.

DOSEAGE AND ADMINISTRATION

Adults
The recommended dose is 150 to 200 mg daily in two, three or four divided. In patients with severe symptoms or disease of osteoarthritis, the total daily dose may be increased to 200 mg or more. For maintenance therapy, the dose of 150 to 200 mg every 12 hours is recommended. Doses up to 300 mg every 24 hours may be necessary for short periods. Flurbiprofen is not recommended for use in children under 12 years.

Geriatric population
Although flurbiprofen is generally well tolerated in the elderly, some patients, especially those with impaired renal function, may demonstrate renal toxicity more clearly than normal. In these cases, flurbiprofen should be used with caution and dose adjustments may be necessary.

Pediatrics
Flurbiprofen is not recommended for use in children under 12 years.

PHARMACOLOGIC PROPERTIES
Flurbiprofen has analgesic, anti-inflammatory and antipyretic properties. It is a member of the non-steroidal anti-inflammatory drug (NSAID) class.

CONTRAINDICATIONS
Flurbiprofen is contraindicated in patients with a history of severe heart failure, renal failure or hepatic failure. It is also contraindicated in patients with severe gastrointestinal disorders.

PRECAUTIONS
Caution is necessary if Froben is given to patients with a history of heart failure or hypertension since these conditions may limit the use of flurbiprofen. Flurbiprofen should not be given to patients who have experienced adverse reactions to other NSAIDs.

OVERDOSAGE
Symptoms of overdosage may include nausea, vomiting and gastrointestinal irritation. Treatment consists of symptomatic therapy and supportive care.

STORAGE
Protect from heat, light and moisture.

HOMESUPPLIED
Froben Tablets are supplied as tablets in blister packs of 30's, (Lo, No N/68090)
Froben 100mg Tablets are supplied in blister packs of 30's, (Lo, No N/68090)

Manufactured by:
Abbott Laboratories (Pakistan) Ltd.
Lahore, Karachi.

01-153R6
patients, as well as patients requiring concurrent low dose aspirin, or who are at high risk of these reactions early in the course of therapy. In the majority of cases, the onset of the reaction occurs within the first month of treatment. Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal inflammation or other allergic symptoms.

Dermatological/Allergic

Sensitization reactions, anaphylaxis, including anaphylactic shock, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported to occur in association with the use of Flurbiprofen. Patients appear to be at highest risk of these reactions early in the course of treatment. In the majority of cases, the onset of the reaction occurs within the first month of treatment. Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal inflammation or other allergic symptoms.

Flurbiprofen should be used with caution in patients with skin disorders such as lupus erythematosus (SLE) and systemic lupus erythematosus, since NSAIDs may increase the risk of these conditions.

Gastrointestinal Use

Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which may be fatal.

Drug Interactions

Concomitant use of some of the following drugs: anti-diabetic agents, anticoagulants, such as warfarin (enhanced effect of anticoagulants), diuretics, lithium, methotrexate, cyclosporine, methotrexate, and lithium, may result in an additive effect to the gastrointestinal toxicity of Flurbiprofen. Flurbiprofen may also increase the risk of bleeding associated with anti-coagulant therapy. Flurbiprofen should not be used for 8-12 days after concomitant administration of heparin, as Flurbiprofen can reduce the effect of heparin.

Pregnancy

The use of Flurbiprofen may impair female fertility and it is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of Flurbiprofen should be considered.

Maturation

Flurbiprofen can cause oligospermia and azoospermia. Anti-epileptic drugs may enhance the risk of teratogenic effects, such as spina bifida.

Lactation

Flurbiprofen should be used with caution during lactation as the level of Flurbiprofen in breast milk is only a small fraction of the maternal dose.

Drug Interactions

Concomitant use of some of the following drugs: anti-diabetic agents, anticoagulants, such as warfarin (enhanced effect of anticoagulants), diuretics, lithium, methotrexate, cyclosporine, methotrexate, and lithium, may result in an additive effect to the gastrointestinal toxicity of Flurbiprofen. Flurbiprofen may also increase the risk of bleeding associated with anti-coagulant therapy. Flurbiprofen should not be used for 8-12 days after concomitant administration of heparin, as Flurbiprofen can reduce the effect of heparin.

Pregnancy

The use of Flurbiprofen may impair female fertility and it is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of Flurbiprofen should be considered.

Maturation

Flurbiprofen can cause oligospermia and azoospermia. Anti-epileptic drugs may enhance the risk of teratogenic effects, such as spina bifida.

Lactation

Flurbiprofen should be used with caution during lactation as the level of Flurbiprofen in breast milk is only a small fraction of the maternal dose.

Drug Interactions

Concomitant use of some of the following drugs: anti-diabetic agents, anticoagulants, such as warfarin (enhanced effect of anticoagulants), diuretics, lithium, methotrexate, cyclosporine, methotrexate, and lithium, may result in an additive effect to the gastrointestinal toxicity of Flurbiprofen. Flurbiprofen may also increase the risk of bleeding associated with anti-coagulant therapy. Flurbiprofen should not be used for 8-12 days after concomitant administration of heparin, as Flurbiprofen can reduce the effect of heparin.

Pregnancy

The use of Flurbiprofen may impair female fertility and it is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of Flurbiprofen should be considered.

Maturation

Flurbiprofen can cause oligospermia and azoospermia. Anti-epileptic drugs may enhance the risk of teratogenic effects, such as spina bifida.

Lactation

Flurbiprofen should be used with caution during lactation as the level of Flurbiprofen in breast milk is only a small fraction of the maternal dose.

Drug Interactions

Concomitant use of some of the following drugs: anti-diabetic agents, anticoagulants, such as warfarin (enhanced effect of anticoagulants), diuretics, lithium, methotrexate, cyclosporine, methotrexate, and lithium, may result in an additive effect to the gastrointestinal toxicity of Flurbiprofen. Flurbiprofen may also increase the risk of bleeding associated with anti-coagulant therapy. Flurbiprofen should not be used for 8-12 days after concomitant administration of heparin, as Flurbiprofen can reduce the effect of heparin.

Pregnancy

The use of Flurbiprofen may impair female fertility and it is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of Flurbiprofen should be considered.

Maturation

Flurbiprofen can cause oligospermia and azoospermia. Anti-epileptic drugs may enhance the risk of teratogenic effects, such as spina bifida.

Lactation

Flurbiprofen should be used with caution during lactation as the level of Flurbiprofen in breast milk is only a small fraction of the maternal dose.

Drug Interactions

Concomitant use of some of the following drugs: anti-diabetic agents, anticoagulants, such as warfarin (enhanced effect of anticoagulants), diuretics, lithium, methotrexate, cyclosporine, methotrexate, and lithium, may result in an additive effect to the gastrointestinal toxicity of Flurbiprofen. Flurbiprofen may also increase the risk of bleeding associated with anti-coagulant therapy. Flurbiprofen should not be used for 8-12 days after concomitant administration of heparin, as Flurbiprofen can reduce the effect of heparin.

Pregnancy

The use of Flurbiprofen may impair female fertility and it is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of Flurbiprofen should be considered.

Maturation

Flurbiprofen can cause oligospermia and azoospermia. Anti-epileptic drugs may enhance the risk of teratogenic effects, such as spina bifida.

Lactation

Flurbiprofen should be used with caution during lactation as the level of Flurbiprofen in breast milk is only a small fraction of the maternal dose.

Drug Interactions

Concomitant use of some of the following drugs: anti-diabetic agents, anticoagulants, such as warfarin (enhanced effect of anticoagulants), diuretics, lithium, methotrexate, cyclosporine, methotrexate, and lithium, may result in an additive effect to the gastrointestinal toxicity of Flurbiprofen. Flurbiprofen may also increase the risk of bleeding associated with anti-coagulant therapy. Flurbiprofen should not be used for 8-12 days after concomitant administration of heparin, as Flurbiprofen can reduce the effect of heparin.

Pregnancy

The use of Flurbiprofen may impair female fertility and it is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of Flurbiprofen should be considered.

Maturation

Flurbiprofen can cause oligospermia and azoospermia. Anti-epileptic drugs may enhance the risk of teratogenic effects, such as spina bifida.

Lactation

Flurbiprofen should be used with caution during lactation as the level of Flurbiprofen in breast milk is only a small fraction of the maternal dose.

Drug Interactions

Concomitant use of some of the following drugs: anti-diabetic agents, anticoagulants, such as warfarin (enhanced effect of anticoagulants), diuretics, lithium, methotrexate, cyclosporine, methotrexate, and lithium, may result in an additive effect to the gastrointestinal toxicity of Flurbiprofen. Flurbiprofen may also increase the risk of bleeding associated with anti-coagulant therapy. Flurbiprofen should not be used for 8-12 days after concomitant administration of heparin, as Flurbiprofen can reduce the effect of heparin.

Pregnancy

The use of Flurbiprofen may impair female fertility and it is not recommended in women attempting to conceive. In women who have difficulty conceiving or who are undergoing investigation of infertility, withdrawal of Flurbiprofen should be considered.

Maturation

Flurbiprofen can cause oligospermia and azoospermia. Anti-epileptic drugs may enhance the risk of teratogenic effects, such as spina bifida.

Lactation

Flurbiprofen should be used with caution during lactation as the level of Flurbiprofen in breast milk is only a small fraction of the maternal dose.

Drug Interactions

Concomitant use of some of the following drugs: anti-diabetic agents, anticoagulants, such as warfarin (enhanced effect of anti-coagulants), diuretics, lithium, methotrexate, cyclosporine, methotrexate, and lithium, may result in an additive effect to the gastrointestinal toxicity of Flurbiprofen. Flurbiprofen may also increase the risk of bleeding associated with anti-coagulant therapy. Flurbiprofen should not be used for 8-12 days after concomitant administration of heparin, as Flurbiprofen can reduce the effect of heparin.